Medizin
Refine
Year of publication
Document Type
- Article (68)
- Book (6)
- Conference Proceeding (4)
Has Fulltext
- yes (78)
Is part of the Bibliography
- no (78)
Keywords
- Cancer (2)
- Cell differentiation (2)
- Gene expression (2)
- Parkinson’s disease (2)
- Podospora anserina (2)
- aging (2)
- autophagy (2)
- brain metastases (2)
- caspase-8 (2)
- epigenetics (2)
- resistance (2)
- 16p11.2 (1)
- 3Cs technology (1)
- AJAP1 (1)
- Adenylyl cyclase (1)
- Adherence junctions (1)
- Adhesion (1)
- Adult neurogenesis (1)
- Anopheles (1)
- Anura (1)
- Apoptosis (1)
- Atelopus carbonerensis (1)
- Atelopus mucubajiensis (1)
- Atelopus tamaense (1)
- Autism (1)
- B cells (1)
- Biochemistry (1)
- Biomarkers (1)
- Bufonidae (1)
- C. elegans (1)
- CAM (1)
- CD95/Fas receptor (1)
- CRISPR/Cas9 (1)
- Cancer detection and diagnosis (1)
- Cell adhesion (1)
- Cell binding (1)
- Cell biology (1)
- Cell signalling (1)
- Cellular imaging (1)
- Colon cancer (1)
- Complexin 1 (1)
- Crispr/Cas (1)
- Cytoplasm (1)
- Cytoplasmic staining (1)
- DUBs (1)
- DYRK1A (1)
- Developmental biology (1)
- Doxorubicin (1)
- Erythropoiesis (1)
- Evolutionary biology (1)
- Extracellular matrix (1)
- Extracellular vesicles (1)
- Fbw7 (1)
- GRADE (1)
- Galleria mellonella (1)
- Gastrointestinal cancer (1)
- HDAC (1)
- HUVEC (1)
- Histology (1)
- Hodgkin lymphoma (1)
- Image analysis (1)
- Intravenous injections (1)
- Ki-67 (1)
- Kynurenine (1)
- Lactation (1)
- Luciferase (1)
- MACE (1)
- MRP4 (1)
- MRSA (1)
- Mammary gland (1)
- Marker genes (1)
- Mcl-1 (1)
- Microglial cells (1)
- Model Organism (1)
- Mouse models (1)
- NXF1 (1)
- Neurons (1)
- Neuroscience (1)
- Optogenetics (1)
- PARK4 (1)
- PINK1 (1)
- PKA (1)
- Phosphorylation (1)
- Plasmodium (1)
- Polo-like kinase 3 (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- RNA Biology (1)
- RNA binding proteins (1)
- ROS (1)
- Rapid eye movement sleep behavior disorder (1)
- Respiratory tract diseases (1)
- SCA34 (1)
- SCA38 (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- Sensory Neuroscience (1)
- Sequence motif analysis (1)
- Sholl analysis (1)
- Splice variants (1)
- Staphylococcus aureus (1)
- T-cell receptor (1)
- TRAIL (1)
- Tools and ressources (1)
- Transcription factors (1)
- Transcriptional control (1)
- Tumor interstitial fluid pressure (1)
- Tumor suppressor protein (1)
- Xenorhabdus (1)
- Yellow fluorescent protein (1)
- acetaminophen (1)
- acid sphingomyelinase (ASMase; Smpd1) (1)
- acute attacks (1)
- adenosine receptors (1)
- adhesion (1)
- advanced glycation end products (1)
- alkaloid (1)
- alpha-synuclein (1)
- alternative 3′ end processing (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anal carcinoma (1)
- astrocytes (1)
- atherosclerosis (1)
- azaindole (1)
- bioacoustics (1)
- brain phosphorylome (1)
- cAMP (1)
- cancer (1)
- cardiovascular disease (1)
- cdk (1)
- cell biology (1)
- cell cycle (1)
- cell growth (1)
- cell migration (1)
- ceramide synthase (CERS2/CERS1) (1)
- chemoradiotherapy (1)
- climate change (1)
- co-crystallization (1)
- comprehensive care (1)
- cross-border (1)
- cyclic depsipeptide (1)
- cyclins (1)
- diabetes mellitus (1)
- differentiation (1)
- docking studies (1)
- eNPP2 (1)
- endothelial cells (1)
- environment (1)
- esterification (1)
- exosomes (1)
- fasting (1)
- fatty acid elongase (Elovl1/4/5) (1)
- fluorescent dye (1)
- focal adhesion (1)
- function, sorting (1)
- gRNA library (1)
- gene regulation (1)
- genetics and genomics (1)
- genome-wide (1)
- glucose (1)
- glycation (1)
- guideline (1)
- harmine (1)
- hematopoiesis (1)
- hemodialysis (1)
- hereditary angioedema, (1)
- host cell response (1)
- human (1)
- i-AAA protease (1)
- iCLIP (1)
- immune system (1)
- immunotherapy (1)
- imported malaria (1)
- individualized therapy (1)
- inducible nitric oxide synthase (1)
- insecticide (1)
- integrin (1)
- ischemia (1)
- kidney disease (1)
- kinase regulation (1)
- leukemia (1)
- leukodystrophy (1)
- life span (1)
- lifespan (1)
- liver damage (1)
- local control (1)
- long-term prophylaxis (1)
- mRNA (1)
- mRNA export (1)
- magnetic resonance imaging (1)
- malaria elimination (1)
- mechanical stimuli (1)
- metabolism (1)
- metabolites (1)
- metabolomics (1)
- metastasis (1)
- metastatic cancer (1)
- methylglyoxal (1)
- miRNA (1)
- microglia (1)
- microtubular cytoskeleton (1)
- microtubule-targeting agents (1)
- mitochondria (1)
- monoamine oxidase A (1)
- mtor (1)
- natural compounds (1)
- natural product (1)
- nematophin (1)
- neurons (1)
- neutral ceramidase (Asah2) (1)
- neutral sphingomyelinase (Smpd3) (1)
- next-generation sequencing (1)
- non-coding RNA (1)
- nuclear hormone receptor (1)
- olivo-ponto-cerebellar atrophy (OPCA) (1)
- oncogene (1)
- oncogenes (1)
- ovarian cancer (1)
- p44/42 MAPK (1)
- paclitaxel (1)
- polo-like kinase (1)
- pre-clinical models (1)
- prostate cancer (1)
- protein kinases (1)
- protein quality control (1)
- proteomics (1)
- quality of life (1)
- quantification (1)
- radioresponse (1)
- radiotherapy (1)
- recommendations (1)
- self-administration (1)
- sensitization (1)
- serine palmitoyltransferase 2 (Sptlc2) (1)
- short-term prophylaxis (1)
- signal transducer and activator of transcription-1 (1)
- spectroscopy (1)
- stress response (1)
- structure–activity relationships (1)
- synaptic signaling (1)
- szentiamide (1)
- temperature (1)
- temsirolimus (1)
- teratoma (1)
- transcription factors (1)
- tumor cell proliferation (1)
- tumor microenviroment (1)
- type I interferon (1)
- valproic acid (1)
- vascular remodeling (1)
- vector (1)
- α-synuclein (1)
Institute
- Biowissenschaften (78) (remove)
The β-carboline alkaloid harmine is a potent DYRK1A inhibitor, but suffers from undesired potent inhibition of MAO-A, which strongly limits its application. We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of β-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition. Based on evidence from published crystal structures of harmine bound to each of these enzymes, we performed systematic structure modifications of harmine yielding DYRK1A-selective inhibitors characterized by small polar substituents at N-9 (which preserve DYRK1A inhibition and eliminate MAO-A inhibition) and beneficial residues at C-1 (methyl or chlorine). The top compound AnnH75 remains a potent DYRK1A inhibitor, and it is devoid of MAO-A inhibition. Its binding mode to DYRK1A was elucidated by crystal structure analysis, and docking experiments provided additional insights for this attractive series of DYRK1A and MAO-A inhibitors.